These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 6861860)

  • 41. Pharmacodynamics and pharmacokinetics of the basic triamterene analogue dimethylaminohydroxypropoxytriamterene.
    Priewer H; Kraft H; Mutschler E
    Arzneimittelforschung; 1985; 35(11):1688-91. PubMed ID: 4091871
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The concentration-dependent disposition of intravenous p-aminohippurate in subjects with normal and impaired renal function.
    Prescott LF; Freestone S; McAuslane JA
    Br J Clin Pharmacol; 1993 Jan; 35(1):20-9. PubMed ID: 8448064
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Variations in the fate of triameterene.
    Pruitt AW; Winkel JS; Dayton PG
    Clin Pharmacol Ther; 1977 May; 21(5):610-9. PubMed ID: 870273
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Excretion of triamterene and its metabolite in triamterene stone patients.
    Ettinger B
    J Clin Pharmacol; 1985; 25(5):365-8. PubMed ID: 4031113
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Studies on the possible correlations between in vitro and in vivo data using commercial triamterene formulations (author's transl)].
    Stüber W; Mutschler E; Steinbach D
    Arzneimittelforschung; 1980; 30(7):1158-63. PubMed ID: 7191300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Tianeptine and its main metabolite. Disposition in chronic renal failure and haemodialysis.
    Salvadori C; Merdjan H; Brouard R; Baumelou A; Nicot G; Friès D
    Fundam Clin Pharmacol; 1990; 4(6):663-71. PubMed ID: 2096105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renal excretion of sulphamethoxazole and its metabolite N4-acetylsulphamethoxazole in patients with impaired kidney function.
    Vree TB; Hekster YA; Damsma JE; van Dalen R; Hafkenscheid JC; Friesen WT
    Ther Drug Monit; 1981; 3(2):129-35. PubMed ID: 7268825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effects of triamterene and its phase I and phase II metabolities on sodium transport of the isolated frog skin.
    Kramer HJ; Rörig M; Völger KD
    Pharmacology; 1981; 23(3):149-55. PubMed ID: 6974360
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Drug induced nephrolithiasis: observation of an oxalate and hydroxylated triamterene stone (author's transl)].
    Baudin S; Rodrigue H
    Nephrologie; 1980; 1(4):183-5. PubMed ID: 7301028
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of renal failure on the pharmacokinetics of ethyl loflazepate (Victan) in man.
    Ba BB; Iliadis A; Durand A; Berger Y; Necciari J; Cano JP
    Fundam Clin Pharmacol; 1989; 3(1):11-7. PubMed ID: 2714728
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Amantadine hydrochloride pharmacokinetics in patients with impaired renal function.
    Wu MJ; Ing TS; Soung LS; Daugirdas JT; Hano JE; Gandhi VC
    Clin Nephrol; 1982 Jan; 17(1):19-23. PubMed ID: 7035042
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pharmacokinetics of disopyramide in patients with chronic renal failure.
    Francois B; Mallein R; Rondelet J; Lussignol M
    Eur J Drug Metab Pharmacokinet; 1983; 8(1):85-92. PubMed ID: 6861798
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Absence of a significant pharmacokinetic interaction between hydrochlorothiazide and triamterene when coadministered.
    Upton RA; Williams RL; Lin ET; Gee WL; Blume CD; Benet LZ
    J Pharmacokinet Biopharm; 1984 Dec; 12(6):575-86. PubMed ID: 6533293
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The kinetics of aminosidine in renal patients with different degrees of renal failure.
    Novarini A; Montanari A; Bruschi G; Rossi E; Borghetti A; Migone L
    Clin Nephrol; 1975 Jul; 4(1):23-4. PubMed ID: 1157346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of norfloxacin in chronic renal failure.
    Arrigo G; Cavaliere G; D'Amico G; Passarella E; Broccali G
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):491-6. PubMed ID: 4055162
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Elimination of oral cimetidine in chronic renal failure and during haemodialysis.
    Bjaeldager PA; Jensen JB; Larsen NE; Hvidberg EF
    Br J Clin Pharmacol; 1980 Jun; 9(6):585-92. PubMed ID: 7387814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Renal clearance of sulphinpyrazone in man.
    Lentjes EG; Russel FG; van Ginneken CA
    Eur J Clin Pharmacol; 1986; 31(4):473-8. PubMed ID: 3816927
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.
    Aronoff GR
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S974-6. PubMed ID: 6085387
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Renal handling of drugs in the healthy elderly. Creatinine clearance underestimates renal function and pharmacokinetics remain virtually unchanged.
    Fliser D; Bischoff I; Hanses A; Block S; Joest M; Ritz E; Mutschler E
    Eur J Clin Pharmacol; 1999 May; 55(3):205-11. PubMed ID: 10379636
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biotransformation and excretion of lorazepam in patients with chronic renal failure.
    Verbeeck R; Tjandramaga TB; Verberckmoes R; De Schepper PJ
    Br J Clin Pharmacol; 1976 Dec; 3(6):1033-9. PubMed ID: 22216526
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.